Daniel Passeri
Chief Executive Officer presso CUE BIOPHARMA, INC.
Patrimonio netto: 254 352 $ in data 31/03/2024
Posizioni attive di Daniel Passeri
Società | Posizione | Inizio | Fine |
---|---|---|---|
CUE BIOPHARMA, INC. | Director/Board Member | 01/08/2016 | - |
Chief Executive Officer | 01/08/2016 | - | |
President | 01/08/2016 | 07/10/2019 |
Storia della carriera di Daniel Passeri
Precedenti posizioni note di Daniel Passeri
Società | Posizione | Inizio | Fine |
---|---|---|---|
CURIS, INC. | Director/Board Member | 01/09/2011 | 01/06/2016 |
Chief Executive Officer | 01/09/2001 | 02/06/2014 | |
Corporate Officer/Principal | 01/11/2000 | 01/09/2001 | |
President | 01/09/2001 | 01/02/2013 | |
Genomic Medicine, Inc.
Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a private company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Corporate Officer/Principal | 01/12/2014 | 01/06/2015 |
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Corporate Officer/Principal | 01/03/1997 | 01/11/2000 |
Boehringer Mannheim Pharmaceuticals Corp. | Corporate Officer/Principal | 01/03/1997 | 01/03/1997 |
Xequel Bio, Inc.
Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Director/Board Member | - | - |
Formazione di Daniel Passeri
Imperial College London | Graduate Degree |
Northeastern University | Undergraduate Degree |
George Washington University Law School | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Regno Unito | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Settori
Health Technology | 5 |
Consumer Services | 4 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
CURIS, INC. | Health Technology |
CUE BIOPHARMA, INC. | Health Technology |
Aziende private | 4 |
---|---|
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Health Technology |
Xequel Bio, Inc.
Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Health Technology |
Genomic Medicine, Inc.
Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a private company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Commercial Services |
Boehringer Mannheim Pharmaceuticals Corp. |
- Borsa valori
- Insiders
- Daniel Passeri
- Esperienza